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Abstract
Background: The benefit of pelvic lymphadenectomy in patients with cancer of the urinary
bladder remains controversial. Though the inclusion of lymph node dissection in conjunction with
radical cystectomy for patients with clinically negative nodes is well accepted, however, the extent
of the nodal dissection remains contentious, particularly in patients with gross disease and T1G3
cancer. The extent of the primary bladder tumor, number of lymph nodes removed and the lymph
node tumor burden are important prognostic variables in patients undergoing cystectomy. We
analyzed the impact of the extent of lymphadenectomy during radical cystectomy on survival in the
contemporary literature.
Methods: A Pubmed search was carried out for the literature published over the last 15 years
using bladder cancer, radical cystectomy, survival, lymphadenectomy and complications as the key
words. We have discussed the extent of lymphadenectomy on survival and its anatomical basis to
determine the optimal number of lymph nodes to be removed and the concept of node density.
Results: Evidence from contemporary literature indicate significantly increased survival rates after
cystectomy in patients with bladder cancer diagnosed with stages III or IV disease who have had
relatively more lymph nodes examined, suggesting that even some patients with higher stage
disease may benefit from extended pelvic lymphadenectomy at the time of cystectomy. Studies also
indicate that more extensive lymphadenectomy significantly improved the prognosis of patients
with bladder cancer, not only by providing prognostic information but perhaps it is also due to its
inherent therapeutic value.
Conclusion: Extended lymph node dissection improves local control and survival. However, in the
absence of controlled randomized trial this remains a dubitable issue.

Background
Bladder cancer is the second most common tumor of the
urogenital tract with transitional cell carcinoma comprising of about 90% of all primary bladder malignancies [1].
Most of these tumors are superficial at initial presentation,

limited to the mucosa, sub-mucosa or lamina propria. In
superficial cancers, recurrence rates after initial treatment
are 50–80% with progression to muscle invasive disease
in 10–25% cases, whereas in muscle invasive disease there
is 50% risk of loco-regional and distant metastasis.
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The transitional cell carcinomas (TCC) originates in the
bladder mucosa, progressively invading the lamina propria and more sequentially involves muscularis propria,
perivesical fat and contiguous pelvic structures with
increasing incidence of lymph node involvement during
progression [2,3].
Radical cystectomy is the corner stone of treatment for
invasive bladder cancers in patients whose medical condition allows major surgical procedure [1,4]. Five-year life
expectancy is 75% for T2 lesions, 40% for T3 and 25% for
T4 lesions [5]. The outcome for bladder cancer patients
have improved primarily because of advances in surgical
technique and better peri-operative care. However 70% of
the patients with node positive disease develop tumor
recurrence if treated by cystectomy alone. Proper staging
of disease and timely institution of adjuvant treatment
could potentially make a difference.
In addition to the evaluation of the primary tumor in a
cystectomy specimen, assessment of the regional lymph
nodes is also important; not only to accurately stage the
disease but also to identify the need for adjuvant treatment. Preoperative imaging studies CT scan or an MRI will
miss microscopic nodal metastasis in up to 70% of the
patients [3,7,8] and this leaves histological evaluation as
the only reliable tool in accurately staging the disease. The
reported incidence of regional lymph node involvement
following radical cystectomy is between 14% and 28%
[[5,6], and [8]]. These rates correlate with the stage of the
tumor; the higher the stage, the higher is the incidence of
the involved lymph nodes [5,10,11]. Lymph node
involvement is associated with increased risk of local
recurrence and disease progression with survival rates varying from 20% to 40% in patients with and without
lymph nodes metastasis respectively [5,10].
Pelvic lymphadenectomy is routinely performed as part of
radical cystectomy for bladder cancers; however, there is
lack of consensus on the intent (therapeutic or diagnostic)
and limits of lymph node dissection. It is most often performed as a staging procedure. Some of the leading
authorities believe that it has a potential therapeutic
adjunct to radical cystectomy [12,13].
The absolute limits or extent of lymphadenectomy for
patients undergoing surgery with a curative intent has not
been precisely defined. The recent guidelines for the treatment of muscle invasive bladder cancer by The European
Association of Urology recommend limited pelvic node
dissection. This consists of removing the tissue in the
obturator fossa in patients undergoing surgery with a curative intent [14]. Whereas several authors have noted an
improved 5-year survival with extensive pelvic lymph
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node dissection in patients with node positive bladder
cancer [2,3,15].
In the present review, we have attempted to analyze the
current literature to see if there is convincing data to support the observation of some authors that extensive pelvic
lymphadenectomy is associated with low pelvic and distant recurrence and survival.

Extent of lymphadenectomy
The minimum number of lymph nodes to be excised in
order to obtain a therapeutic advantage remains an issue
of controversy. Anatomical studies have defined the external and internal iliac lymph nodes and the obturator
nodes as the site of primary lymphatic drainage of the
bladder and the common iliac nodes as the site of secondary drainage, with the trigone and the posterior wall
draining directly into the pre-sacral nodes [16].
The role and extent of lymphadenectomy in bladder cancer is not well-defined, in contrast, patients with gastric
[17], breast [18], and colorectal [19] tumors the impact of
lymphadenectomy has been well studied and there has
been a consensus that complete lymph node dissection
with removal of a minimum number of lymph nodes correlates with improved survival. Guidelines for the management of colon and rectal cancer indicate that at least
12–14 lymph nodes should be retrieved by the pathologist in patients with colorectal cancers [18] and at least 10
lymph nodes in patients with endometrial cancer [20],
but this knowledge is lacking in cases of bladder cancers.
Several authors have postulated that the number of lymph
nodes examined in cystectomy specimen can have an
impact on the outcome of patients treated for primary
bladder cancer [9,13], whereas others have reported an
improved survival with extensive nodal dissection
[15,22]. Extensive lymphadenectomy increases the operating time and theoretically may increase the risk of hemorrhage and lymphocele formation, but studies have not
shown a significant increase in morbidity with this procedure [22].

Number of lymph nodes and impact on survival
Many factors can influence the outcome of patients with
bladder cancer including the T-stage, the N-stage and the
total number of lymph nodes retrieved. Skinner et al, [13]
noted that important prognostic factors included age, gender and lymph nodes status but the number of involved
nodes was the single most important prognostic variable.
Lerner et Al, [2] observed that the 5-year survival probability in cases with 5 or fewer involved nodes was almost
double than those with 6 or more involved nodes. Mills et
Al, [23] studied a group of 83 patients with nodes positive
disease and reported similar results. The median number
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of retrieved nodes was 20/case. A significant survival difference was observed when patients with less than 5
involved nodes were compared with more than 5
involved lymph nodes (p = 0.0027), however this significance was lost on multivariate analysis. Stein et al, [22]
verified the impact of positive nodes on univariate as well
as multivariate analysis with a cut off of 8 involved nodes
[18]. Vieweg et al, [24] reported that in cases with organ
confined disease, there was no survival difference between
N0 and N1 groups but survival benefit consistently
decreased from N1 to N3 disease. Konety et al, [25] studied
20,799 patients treated for primary bladder cancer and
reported similar results. They concluded that regardless of
the tumor stage, at least 14 lymph nodes should be
excised in patients undergoing radical cystectomy. Herr et
al, [26] studied the impact of lymph nodes in a group of
322 patients who underwent pelvic node dissection. They
observed that in patients with pN0 status improved survival and local control was seen when the cut-off was 8
examined lymph nodes. However, in patients with pathologically involved nodes at least 9 lymph nodes should be
removed.

tumors. Patients with a lymph node density of 20% or less
had a better recurrence free survival when compared to
those with more than 20% (p < 0.001), however this
study confined to only the lymph node positive cases, the
lymphadenectomy was done in en bloc fashion, and the
exact anatomical location of the excised lymph nodes was
not known. In an attempt to standardize the extent of dissection, Leissner et al [9] studied a group of 447 patients
who underwent extended lymphadenectomy along with
radical cystectomy for bladder cancer. The guidelines for
lymphadenectomy were to remove obturator, internal,
external and common iliac, pre-sacral and the lymph
nodes on both sides of aortic bifurcation. The mean
number of retrieved nodes was 16.7/patient. They
observed that overall the tumor specific survival (P-value
< 0.013) and disease free survival was significant (P-value
<0.016) when patients with ≥ 16 excised lymph nodes
were compared with those with < 15 nodes removed,
except for those with T-4 lesions. In presence of nodal
metastasis patients only benefited by removal of at least
five metastatic lymph nodes, thus supporting the therapeutic effect of extended lymphadenectomy.

Anatomical extent of dissection

The two possible reasons for better survival in patients
with extended lymphadenectomy were explained by lymphadenectomy resulting in a more accurate staging so
adjuvant therapy may be started earlier. The other possible explanation could be the increased likelihood of
removing nodal tumor deposits. Conclusive evidence
could not be derived from a retrospective studies and literature review.

Poulsen et al, [15] studied the influence of extent of nodal
dissection on survival following radical cystectomy for
bladder cancer. They compared 126 patients who underwent extensive pelvic dissection with proximal limits up
to the bifurcation of aorta and 68 patients who underwent
limited nodal dissection with proximal limits up to the
common iliac vessels. The overall prevalence of nodal
metastasis was slightly higher in patients with extended
dissection as compared to ones with limited dissection.
Extended dissection was associated with an improved 5year recurrence free survival for patients with tumor confined to the bladder (pT3a or less), but this was not true for
tumors penetrating the bladder wall. This was a retrospective, non-randomized study and the anatomical mapping
and the number of retrieved lymph nodes was not mentioned.
Herr et al, [21] introduced the term of lymph node density
indicating the ratio between the numbers of nodes
removed to the number of involved node. They found
ratio based lymph node staging, which reflects the quality
of lymph node dissection, was a significant prognostic
variable for survival and local control in patients with
lymph node positive bladder cancer after radical cystectomy. Later Stein et al, [22] reported their experience of
244 patients with involved lymph nodes treated for primary transitional cell carcinoma of bladder. They reported
that the overall and recurrence free survival was significantly related to pathological subgroup of the primary
bladder tumor, patients with organ-confined disease having a better survival as compared to those with extravesical

Mills et al [23] reported their experience of 83 patients
with node positive tumors who underwent pelvic lymphadenectomy. Anatomical mapping was done in the
group of retrieved nodes. Survival correlated with the
number of lymph nodes, adjuvant chemotherapy, capsular penetration and the site of metastatic nodes. On univariate analysis, survival was better when more than 5
positive lymph nodes was removed however this was not
significant and only lymph node capsular penetration
demonstrated a significant effect on survival. This was
again a retrospective study but only the pelvic lymph
nodes were dissected, therefore the nodal status of the
proximal sites was unknown.
Vazina et al [27] reviewed their results of 176 patients who
were treated with lymph node dissection up to the aortic
bifurcation. The median number of lymph nodes excised
was 25/case. It was observed that the rate of nodal
involvement gradually decreased from pelvic to aortic
sites. They reported that these tumors did not exhibit skip
metastasis as all. The patients except one who had
involvement of lymph nodes at or above the aortic bifurcation or common iliac region also had positive lymph
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nodes in distal (pelvic and peri-vesical) areas. One patient
who had involvement of the common iliac lymph nodes
without involving the distal lymph nodes, had a primary
lesion in the trigone explaining this to be presumably due
to direct lymphatic drainage of the trigone area to the
common iliac region. Bochner et al, [28] reported the survival status of 144 patients who were operated for primary
bladder cancer, out of whom 56 underwent standard pelvic node dissection whereas 88 patients had extended dissection. Though, the yield of nodes was greater in
extended dissection than in standard dissection, but both
types had a similar percentage of patients with positive
lymph nodes, however extended lymphadenectomy provided better prognostic information through a more accurate evaluation of the total number of lymph nodes
excised or the number of involved lymph nodes. Extended
lymphadenectomy identified 33% of patients with microscopic nodal metastasis involving the common iliac
lymph nodes, explaining the therapeutic value of pelvic
dissection. This is also supported by a European study of
a group of 290 patients, who underwent extended radical
lymphadenectomy along with radical cystectomy [29]. In
this series, it was observed that 57% of patients with
lymph node involvement at level I had nodal metastasis
at level II and 31% had level III nodes involved. Similarly,
35% patients with level II nodes involved were found to
have level III nodal involvement, hence they concluded
with a strong recommendation for extended lymphadenectomy in all patients undergoing radical cystectomy for bladder cancer with a curative intent. The three
lymphadenectomy levels were defined by the authors as;
level I, distal to the bifurcation of common iliac artery,
level II distal aortic bifurcation up to level I and level III
proximal to aortic bifurcation.

Conclusion
More than half the patients with locally advanced (pT3a,
pT3b,pT4a and/ or pN+) treated by radical surgery will have
disease progression in five years. Adequate staging affects
the outcome of patients with bladder cancer. Such information is important not only for therapy and prognosis,
but also in identifying individuals for adjuvant treatment.
Evidence from contemporary studies indicates that more
extensive lymphadenectomy significantly improved the
prognosis of patients with bladder cancer. A growing body
of evidence suggests that an extended lymph node dissection may provide not only improved prognostic information, but also a clinically significant therapeutic benefit
for both lymph node-positive and -negative patients
undergoing radical cystectomy. However, in the absence
of randomized controlled trial, the scientific value of current evidence is at best level 2.
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